Vmbook Online ordering

Scolr Pharma Inc

SciClone Pharmaceuticals (SCLR) is a biopharmaceutical company focused on the development, manufacturing, and commercialization of pharmaceutical products, primarily in China. The company's lead product is ZADaxin (thymalfasin), an immunomodulator used to treat hepatitis B.

In terms of financials, SciClone reported revenue of $75.4 million for the full year 2020, representing a decrease of 15% compared to the previous year. The company's net income for the year was $14.3 million, or $0.65 per share, compared to $27.3 million, or $1.21 per share, in 2019.

As for growth, SciClone has seen declining revenue in recent years, primarily due to the loss of exclusivity for several of its products in China. However, the company has made efforts to diversify its product portfolio and expand into new markets, including the United States. In 2020, SciClone announced positive topline results from a Phase 3 clinical trial of ZADaxin for the treatment of Hepatitis B in the United States, which could represent a significant growth opportunity for the company if approved by the FDA.

Overall, while SciClone has faced some challenges in recent years, the company's focus on immunotherapy and its efforts to expand into new markets may present growth opportunities in the future. Investors interested in SciClone should continue to monitor the company's financial performance, regulatory approvals, and progress in expanding its product portfolio.